Gotrade News - Life sciences penny stocks are drawing renewed investor attention in 2026 as pipeline catalysts and landmark partnerships converge. OmniAb, AbCellera Biologics, and Pacific Biosciences each offer distinct angles on the emerging antibody and genomics opportunity.
The broader life sciences sector has seen improved conditions since late 2025, with positive trends in both stock market performance and venture capital investment noted by CBRE. 2026 is shaping up to be a year when several of these smaller-cap names deliver on multi-year build-up.
Key Takeaways:
- OmniAb has 107 active partners and 407 programs, with over $3 billion in contracted milestones and 32 active clinical programs as of early 2026.
- AbCellera Biologics holds roughly $680 million in liquidity and expects a Phase II readout for its lead internal asset ABCL635 in Q3 2026.
- Pacific Biosciences secured a landmark deal for the Trillion Gene Atlas in March 2026, partnering with Anthropic and NVIDIA to sequence 100,000 samples across 31 countries.
OmniAb (NASDAQ: OABI) operates a technology platform that creates and screens diverse antibody repertoires, licensing its discovery tools to pharma and biotech companies. As of early 2026, the company counts 107 active partners and 407 programs with over $3 billion in contracted milestones, according to the Q4 2025 earnings call.
OmniAb's average royalty rate across its antibody portfolio stands at approximately 3.4%. Recent milestones include Merck KGaA advancing M9140 to Phase III trials and Teva securing new funding for TEV-'408, signaling clinical acceleration in its partner network.
The company's OmniUltra platform is the first transgenic chicken producing antibodies with ultra-long CDRH3 structures, a feature typically found in bovine antibodies with unique therapeutic potential. Management called 2026 "the strongest calendar of near-term events in recent memory" during the Q4 earnings call.
OABI opened at $1.50 on April 11, 2026, per market data. Nine Wall Street analysts have set a median price target of $8.00, ranging from $3.00 to $11.00, reflecting substantial asymmetric upside if clinical milestones convert.
AbCellera Shifts to Internal Pipeline
AbCellera Biologics (NASDAQ: ABCL) made a definitive strategic pivot in 2023, ramping down its partnership licensing model to concentrate fully on its internal drug pipeline. The company's platform integrates single-cell screening, microfluidics, high-throughput sequencing, and AI to accelerate early-stage antibody discovery.The lead internal asset ABCL635 is a first-in-class NK3R antibody targeting menopausal vasomotor symptoms, designed as a once-monthly subcutaneous injection. An 80-patient Phase II readout is expected in Q3 2026, likely after Labor Day, per commentary at the JPMorgan Healthcare Conference in January 2026.
Additional pipeline assets include ABCL575, ABCL688 (autoimmune), and ABCL386 (oncology), each described as potential first-in-class candidates. AbCellera expects a data update for ABCL575 by year-end 2026.
AbCellera reported roughly $680 million in liquidity with an operating cash burn of approximately $30 million per quarter, providing what management calls a multi-year runway. The stock has risen approximately 81.6% over the past year, far outpacing the S&P 500's 15.3% return over the same period, according to market data.
Pacific Biosciences Wins Trillion Gene Atlas Deal
Pacific Biosciences (NASDAQ: PACB) secured a landmark agreement in March 2026 when Basecamp Research selected its HiFi sequencing technology to power the Trillion Gene Atlas initiative. The program aims to expand known evolutionary genetic diversity 100-fold by sequencing approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents.
PacBio's Revio system and SPRQ-Nx chemistry will generate large-scale environmental and host-associated metagenomic data for the program. CEO Christian Henry stated that "HiFi sequencing is the ideal data type for developing AI-driven insights to drive future therapeutic discoveries," per the official press release.
The Trillion Gene Atlas brings together Anthropic, NVIDIA, and Ultima Genomics as collaborating partners, with PacBio serving as the core sequencing provider. Analysts describe the deal as a structurally important catalyst that should add meaningful incremental revenue and accelerate gross margin improvement.
PACB stock was trading near $1.42 as of late March 2026, with a consensus analyst price target of $4.32. The Trillion Gene Atlas and forthcoming SPRQ-Nx platform updates are viewed as key 2026–2027 catalysts for the stock's re-rating.
If you want to gain exposure to the biotech and life sciences sector, AbCellera Biologics is available on Gotrade alongside hundreds of other US-listed stocks. Gotrade lets you buy fractional shares with no minimum, so you can start investing in emerging biotech names at any budget.
The next major catalysts to watch are the ABCL635 Phase II readout expected in Q3 2026 and continued Trillion Gene Atlas sample sequencing updates from PacBio throughout the year. Progress on OmniAb's 32 active clinical programs will also serve as a running scorecard for the antibody discovery platform model.
Sources:
- OmniAb Q4 2025 Earnings Call Transcript - Yahoo Finance
- AbCellera Pivots to Internal Pipeline at JPMorgan - Yahoo Finance
- Basecamp Research Selects PacBio HiFi for Trillion Gene Atlas - GlobeNewswire
- 8 Best Life Sciences Penny Stocks to Buy - Insider Monkey
